Seven-day course of treatment – 250 mg three times daily for seven consecutive days. There is some indication from controlled comparative studies that cure rates as determined by vaginal smears and signs and symptoms, may be higher after a seven-day course of treatment than after a one-day treatment regimen.

The dosage regimen should be individualized. Single-dose treatment can assure compliance, especially if administered under supervision, in those patients who cannot be relied on to continue the seven-day regimen. A seven-day course of treatment may minimize reinfection by protecting the patient long enough for the sexual contacts to obtain appropriate treatment. Further, some patients may tolerate one treatment regimen better than the other.

Pregnant patients should not be treated during the first trimester. In pregnant patients for whom alternative treatment has been inadequate, the one-day course of therapy should not be used, as it results in higher serum levels which can reach the fetal circulation.

When repeat courses of the drug are required, it is recommended that an interval of four to six weeks elapse between courses and that the presence of the trichomonad be reconfirmed by appropriate laboratory measures. Total and differential leukocyte counts should be made before and after re-treatment.

In the Male

Treatment should be individualized as it is for the female.

Amebiasis

Adults

For acute intestinal amebiasis (acute amebic dysentery): 750 mg orally three times daily for 5 to 10 days.

For amebic liver abscess: 500 mg or 750 mg orally three times daily for 5 to 10 days.

Pediatric patients: 35 to 50 mg/kg/24 hours, divided into three doses, orally for 10 days.

Anaerobic Bacterial Infections

In the treatment of most serious anaerobic infections, intravenous Axcel Metronidazole is usually administered initially.

The usual adult oral dosage is 7.5 mg/kg every six hours (approx. 500 mg for a 70-kg adult). A maximum of 4 g should not be exceeded during a 24-hour period.

The usual duration of therapy is 7 to 10 days; however, infections of the bone and joint, lower respiratory tract, and endocardium may require longer treatment.

Dosage Adjustments

Patients with Severe Hepatic Impairment

For patients with severe hepatic impairment (Child-Pugh C), the dose of Axcel Metronidazole should be reduced by 50%.

Patients Undergoing Hemodialysis

Hemodialysis removes significant amounts of Axcel Metronidazole and its metabolites from systemic circulation. The clearance of Axcel Metronidazole will depend on the type of dialysis membrane used, the duration of the dialysis session, and other factors. If the administration of Axcel Metronidazole cannot be separated from the hemodialysis session, supplementation of Axcel Metronidazole dosage following the hemodialysis session should be considered, depending on the patient's clinical situation.

More about Axcel Metronidazole (Axcel Metronidazole)

Side Effects
During Pregnancy or Breastfeeding
Dosage Information
Drug Images
Drug Interactions
Support Group
Pricing & Coupons
En Espanol
152 Reviews - Add your own review/rating
Generic Availability

Consumer resources

Axcel Metronidazole
Axcel Metronidazole capsules
Axcel Metronidazole
Oral,
Intravenous (Advanced Reading)

Other brands: Metro

Professional resources

Axcel Metronidazole (AHFS Monograph)
Axcel Metronidazole (FDA)

Other formulations

Axcel Metronidazole IV
Axcel Metronidazole ER
Axcel Metronidazole

Related treatment guides

Bacterial Infection
Helicobacter Pylori Infection
Trichomoniasis
Crohn's Disease, Acute
Amebiasis
More (24) »

What other drugs will affect Axcel Metronidazole?

Tell your doctor about all other medicines you use, especially:

cimetidine (Tagamet);
seizure medication such as phenytoin (Dilantin) or phenobarbital (Luminal, Solfoton);
a blood thinner such as warfarin (Coumadin, Jantoven);
lithium (Lithobid, Eskalith, others); or
disulfiram (Antabuse).

This list is not complete and other drugs may interact with Axcel Metronidazole. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

Axcel Metronidazole interactions

sponsored

Disulfiram

Psychotic reactions have been reported in alcoholic patients who are using Axcel Metronidazole and disulfiram concurrently. Axcel Metronidazole should not be given to patients who have taken disulfiram within the last two weeks.

Alcoholic Beverages

Abdominal cramps, nausea, vomiting, headaches, and flushing may occur if alcoholic beverages or products containing propylene glycol are consumed during or following Axcel Metronidazole therapy.

Warfarin And Other

Oral Anticoagulants

Axcel Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. When Axcel Metronidazole is prescribed for patients on this type of anticoagulant therapy, prothrombin time and INR should be carefully monitored.

Lithium

In patients stabilized on relatively high doses of lithium, short-term Axcel Metronidazole therapy has been associated with elevation of serum lithium and, in a few cases, signs of lithium toxicity. Serum lithium and serum creatinine levels should be obtained several days after beginning Axcel Metronidazole to detect any increase that may precede clinical symptoms of lithium intoxication.

Busulfan

Axcel Metronidazole has been reported to increase plasma concentrations of busulfan, which can result in an increased risk for serious busulfan toxicity. Axcel Metronidazole should not be administered concomitantly with busulfan unless the benefit outweighs the risk. If no therapeutic alternatives to Axcel Metronidazole are available, and concomitant administration with busulfan is medically needed, frequent monitoring of busulfan plasma concentration should be performed and the busulfan dose should be adjusted accordingly.

Drugs That Inhibit CYP450 Enzymes

The simultaneous administration of drugs that decrease microsomal liver enzyme activity, such as cimetidine, may prolong the half-life and decrease plasma clearance of Axcel Metronidazole.

Drugs That Induce CYP450 Enzymes

The simultaneous administration of drugs that induce microsomal liver enzymes, such as phenytoin or phenobarbital, may accelerate the elimination of Axcel Metronidazole, resulting in reduced plasma levels; impaired clearance of phenytoin has also been reported.

Drug/Laboratory Test Interactions

Axcel Metronidazole may interfere with certain types of determinations of serum chemistry values, such as aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT), lactate dehydrogenase (LDH), triglycerides, and glucose hexokinase. Values of zero may be observed. All of the assays in which interference has been reported involve enzymatic coupling of the assay to oxidation-reduction of nicotinamide adenine dinucleotide (NAD- NADH). Interference is due to the similarity in absorbance peaks of NADH (340 nm) and Axcel Metronidazole (322 nm) at pH 7.

sponsored

References

DailyMed. "BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
FDA/SPL Indexing Data. "140QMO216E: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
MeSH. "Anti-Infective Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Axcel Metronidazole are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Axcel Metronidazole. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported frequency of use

No survey data has been collected yet

Consumer reported doses